BIM
TRAW icon

Bogle Investment Management’s Traws Pharma TRAW Stock Holding History

Bogle Investment Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3
Closed -$1.22M – 392
2014
Q1 		$1.22M Buy
+3
New +$1.81M 0.08% 259

Other funds holding TRAW

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Bogle Investment Management's TRAW Position: Q2 2014 in Review

Bogle Investment Management sold out of Traws Pharma (TRAW) in Q2 2014, closing a stake of 3 shares — an estimated $1.22M sold.

Bogle Investment Management first reported a position in TRAW in Q1 2014 and held it in 1 quarter. The position peaked at $1.22M in Q1 2014. 13 funds tracked by Wall St. Rank hold TRAW as of Q2 2014.

  • Bogle Investment Management reported no remaining Traws Pharma position as of Q2 2014 after selling out during the quarter.
  • Bogle Investment Management sold 3 Traws Pharma shares in Q2 2014, an estimated $1.22M.
  • Bogle Investment Management first reported a position in Traws Pharma in Q1 2014 and held it in 1 quarter.
  • Bogle Investment Management's Traws Pharma position peaked at $1.22M in Q1 2014.
  • 13 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2014.

Based on Bogle Investment Management's 13F filing for Q2 2014, filed 14 Aug 2014.